En las noticias
Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
Gateway for Cancer Research accelerates practice-changing clinical trials to cancer research by harnessing the unrelenting passion of the research community and empowering patients to triumph over their disease. All of this is guided by a clear vision: To shape a world in which a cancer diagnosis is no longer feared.
Global Health Dialogues with Princess Dina and Dr. Garo Armen
Garo H. Armen, PhD, Chairman and Chief Executive Officer, Agenus and Princess Dina explore the promise and limits of immunotherapy.
The Old System Failed Patients. Change Must Go Further and Faster
Garo H. Armen, PhD, Chairman and Chief Executive Officer, Agenus provides perspectives on further changes needed to support innovations for patients
Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
An in-depth profile of Dr. Nicholas DeVito on why immunotherapy should come first—exploring Bot/Bal, trial design, and how sequencing can drive durable cancer control.
Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite stable metastatic colorectal cancer without liver metastases.
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
Neoadjuvant botensilimab and balstilimab showed high MPR rates in MSS and MSI-H CRC, with no recurrences reported.
3 Forbes Road
Lexington, Massachusetts 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200